title: Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
abstract: Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.
authors.affiliation: Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Ikeda
authors.forename: Lee C
authors.initials: LC
authors.lastname: Vermeulen
authors.forename: Elim
authors.initials: E
authors.lastname: Lau
authors.forename: Zhisheng
authors.initials: Z
authors.lastname: Jiang
authors.forename: Marcia
authors.initials: M
authors.lastname: Pomplun
authors.forename: Jill M
authors.initials: JM
authors.lastname: Kolesar